IQVIA Holdings Inc. (IQV): Billionaire David Tepper Makes Minor Adjustment
Billionaire David Tepper's Appaloosa Management LP has made a minor 1.7% reduction in its IQVIA Holdings Inc. (IQV) stake in Q4 2025, now holding 280,000 shares. This adjustment follows previous reductions since Q2 2025. The company is gaining Wall Street interest due to its IQVIA.ai platform, powered by NVIDIA, and normalization of trial cancellations, contributing to a high revenue visibility through 2027.
Citi Maintains IQVIA Holdings(IQV.US) With Hold Rating, Maintains Target Price $200
Citi has reiterated its Hold rating on IQVIA Holdings (IQV.US), maintaining a target price of $200 for the company's shares. This action indicates Citi's continued neutral outlook on IQVIA's stock performance.
IQVIA Holdings Inc. stock underperforms Monday when compared to competitors
IQVIA Holdings Inc. (IQV) shares fell by 1.47% to $170.72 on Monday, despite an overall positive trading session for the stock market where the S&P 500 and Dow Jones Industrial Average both rose. This decline ended a four-day winning streak for the company's stock. The article highlights that IQVIA's performance underperformed its competitors on this specific trading day.
IQVIA Holdings Inc. (IQV) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of IQVIA Holdings Inc. (IQV) stock, including its current price, historical data, key financial metrics, and performance against benchmarks like the S&P 500. It also details the company's business segments, analyst ratings, and allows for comparison with similar companies in the Diagnostics & Research industry. The page reflects a recent stock price of $173.26 with a slight increase and notes a "Buy" rating upgrade from TD Cowen.
IQVIA (IQV) Launches IQVIA.ai Unified Agentic AI Platform with Nvidia
IQVIA Holdings Inc. (NYSE: IQV) has launched IQVIA.ai, a unified agentic AI platform developed in collaboration with Nvidia, designed for the life sciences industry. The platform aims to enhance operational efficiency and decision-making across clinical, commercial, and real-world domains by integrating IQVIA’s healthcare-grade AI and data assets with Nvidia’s advanced technology. This system, already being adopted by top pharmaceutical companies, allows for the orchestration of tasks across multiple data sources and will expand its capabilities with additional features planned for release in Q4 2026.
IQVIA (IQV) Launches IQVIA.ai Unified Agentic AI Platform with Nvidia
IQVIA Holdings Inc. (IQV) has launched IQVIA.ai, a new unified agentic AI platform developed in collaboration with Nvidia, specifically designed for the life sciences industry. This platform aims to enhance operational efficiency and decision-making across clinical, commercial, and real-world domains by integrating IQVIA's healthcare-grade AI and data with Nvidia's advanced technology. Many top pharmaceutical companies have already incorporated IQVIA's agents into their workflows, and the platform is set to expand its capabilities with more features planned for Q4 2026.
Illumina (Nasdaq:ILMN) - Stock Analysis
This Simply Wall St report provides an in-depth stock analysis of Illumina (Nasdaq:ILMN), evaluating its valuation, future growth, past performance, financial health, dividends, management, and ownership. The analysis highlights that Illumina is trading below its estimated fair value, with earnings projected to grow, and the company recently became profitable. Various analyst narratives present differing views on the company's future, focusing on clinical genomics expansion, competitive challenges, and strategic product advancements.
Citigroup Maintains IQVIA Holdings (IQV) Neutral Recommendation
Citigroup has reiterated its Neutral rating for IQVIA Holdings (IQV). This indicates that the analyst firm believes the stock is currently fairly valued and does not expect significant upward or downward price movements in the near future. Investors should consider this perspective when evaluating IQVIA Holdings.
Aberdeen Group plc Has $43.44 Million Stake in IQVIA Holdings Inc. $IQV
Aberdeen Group plc significantly increased its stake in IQVIA Holdings Inc. by 39.6% in Q4, bringing its total holding to 192,696 shares valued at $43.44 million. Other institutional investors also adjusted their positions in the medical research company. IQVIA exceeded Q4 earnings expectations with $3.42 EPS and 10.3% year-over-year revenue growth, leading analysts to maintain an average "Buy" rating with an average target price of $229.13.
Revvity, Inc. (RVTY) stock price, news, quote and history
This Yahoo Finance page provides comprehensive financial information for Revvity, Inc. (RVTY), including its current stock price, dividend announcements, historical performance data, and key metrics. It also offers an overview of the company's health sciences solutions, its market position in diagnostics and research, and analyst insights. The page enables users to compare RVTY with similar companies in the Diagnostics & Research industry.
HF Advisory Group LLC Buys 146,444 Shares of IQVIA Holdings Inc. $IQV
HF Advisory Group LLC significantly increased its stake in IQVIA Holdings Inc. by 1,791.6% in Q4, acquiring 146,444 shares to hold a total of 154,618 shares valued at approximately $34.85 million. This makes IQVIA the fund's 11th largest position. The medical research company currently holds a consensus "Buy" rating from analysts with an average price target of $229.13, and recently reported strong quarterly earnings, surpassing analyst estimates for both EPS and revenue.
VNRX|VolitionRX Ltd|Price:0.200|Chg%:-0.00
VolitionRX Ltd (VNRX) shows weak fundamentals but high growth potential, with its revenue growing an average of 122.80% year-on-year over the past three years. The stock is considered fairly valued within its industry, despite a recent 14.25% drop and a current analyst "Buy" rating with upside potential of over 900%. Institutional ownership is high, though holdings decreased by 21.74% last quarter.
Healthcare: Increased Clarity on Drug Pricing and Tariffs Led to a Rebound in Q1
The Morningstar Healthcare Index, after lagging due to drug pricing uncertainty and tariffs, is expected to see solid performance in 2026, driven by its defensive nature, innovation, and benefits from AI. The sector is considered undervalued overall, with healthcare plans and devices looking most attractive. AI is anticipated to significantly reduce the time required to bring new pharmaceuticals to market, benefiting biopharma.
IQVIA Holdings Inc. stock outperforms competitors on strong trading day
IQVIA Holdings Inc. (IQV) stock rose 1.09% to $172.40 on Wednesday, outperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also saw gains, rising 0.72% and 0.48% respectively. This marks the third consecutive day of gains for IQVIA Holdings.
IQVIA Holdings Inc. $IQV Stake Lifted by J. Safra Sarasin Holding AG
J. Safra Sarasin Holding AG significantly increased its stake in IQVIA Holdings Inc. by 174.3% in the fourth quarter, now owning 12,827 shares valued at $2.89 million. Several other institutional investors also adjusted their holdings, with a large percentage of IQVIA stock owned by hedge funds. Analysts have issued varied ratings, but the company generally holds a "Buy" consensus with an average target price of $229.13.
Positive Outlook for Narrow-Moat Iqvia Supported by Durable Demand, AI Innovation, and Execution
Iqvia, formed from the merger of Quintiles and IMS Health, is a leader in contract research organizations and life sciences data. The company benefits from durable demand, AI innovation, and strong execution. This positive outlook is supported by its strong position in real-world evidence and robust business strategy.
Progyny (NASDAQ: PGNY) schedules virtual 2026 meeting; board, audit ratification on ballot
Progyny (NASDAQ: PGNY) has scheduled its 2026 virtual annual meeting for May 21, 2026, with a record date of March 27, 2026, and 78.3 million shares outstanding. Stockholders will vote on the election of three Class I directors, ratification of Ernst & Young LLP as the independent auditor, an advisory vote on executive compensation, and two amendments to the Certificate of Incorporation to eliminate certain supermajority voting requirements. The proposed amendments aim to streamline governance by changing the voting threshold for several corporate actions from two-thirds to a simple majority of outstanding shares.
IQVIA Holdings Inc. stock rises Tuesday, still underperforms market
IQVIA Holdings Inc. (IQV) saw its stock rise by 2.64% on Tuesday, closing at $170.54. Despite this gain, the company's performance underperformed the broader market, which experienced a favorable trading session with the S&P 500 Index and Dow Jones Industrial Average rising more significantly. This marked the second consecutive day of gains for IQVIA stock.
195,165 Shares in IQVIA Holdings Inc. $IQV Purchased by Vaughan Nelson Investment Management L.P.
Vaughan Nelson Investment Management L.P. recently purchased 195,165 shares of IQVIA Holdings Inc. (NYSE:IQV) stock, valued at approximately $43.99 million, representing a new stake in the company. Other institutional investors have also adjusted their holdings in IQVIA. Analysts generally rate IQVIA as a "Buy" with a consensus price target of $229.13, following strong Q4 earnings where the company beat estimates and provided positive FY2026 guidance.
AI-led selloff in contract research firms may be misjudging disruption risk
Shares of contract research organizations (CROs) have dropped due to fears that AI advancements could allow drugmakers to conduct clinical trials in-house. However, industry experts and analysts argue that the selloff overestimates AI's ability to replace CROs' core services, such as global patient recruitment and trial execution, suggesting that AI is more likely to enhance efficiency rather than disrupt the sector. While investors are concerned, analysts believe there's no evidence of pharma companies reducing CRO spending due to AI, viewing it as a potential tailwind instead of a threat.
IQVIA Holdings Inc. stock outperforms competitors on strong trading day
Shares of IQVIA Holdings Inc. (IQV) rose 1.41% to $166.16 on Monday, outperforming the broader market. This occurred during a mixed trading session where the Dow Jones Industrial Average saw a slight increase, while the S&P 500 Index declined. The company's stock is currently 32.74% below its 52-week high.
Behavioral Patterns of IQV and Institutional Flows - Stock Traders Daily
This article analyzes Iqvia Holdings Inc. (NYSE: IQV) using AI models to identify behavioral patterns and institutional trading flows. It suggests a weak near and mid-term sentiment, potentially challenging a long-term positive outlook, and outlines specific trading strategies (position, momentum, and risk hedging) with detailed entry, target, and stop-loss levels based on different risk profiles. The analysis also provides multi-timeframe signal strengths and support/resistance levels for the stock.
IQVIA Holdings Inc (IQV) Shares Gap Down to $163.85 on Mar 30
IQVIA Holdings Inc (IQV) shares fell 3.28% in mid-day trading on March 30, reaching an intraday low of $162.36 before closing at $163.85. This puts the stock significantly below its 52-week high, while analysts maintain an "Outperform" rating with an average target price implying a 44.47% upside. GuruFocus' estimated fair value (GF Value) suggests an even greater potential upside of 60.57%.
Truist Financial Maintains IQVIA Holdings(IQV.US) With Buy Rating
Truist Financial has reaffirmed its Buy rating on IQVIA Holdings (IQV.US). This indicates a continued positive outlook from the financial institution regarding the company's stock performance.
SG Americas Securities LLC Buys 26,161 Shares of IQVIA Holdings Inc. $IQV
SG Americas Securities LLC increased its stake in IQVIA Holdings Inc. by 108.8% in Q4, acquiring an additional 26,161 shares, bringing its total to 50,206 shares valued at $11.32 million. IQVIA reported strong Q4 earnings, beating analyst estimates with EPS of $3.42 and revenue of $4.36 billion, and provided positive FY2026 guidance. Wall Street analysts maintain a "Buy" consensus rating for IQVIA, with an average target price of $229.13.
GSK’s hepatitis B drug accepted for China regulatory review
GSK announced that China's National Medical Products Administration has accepted a new drug application for bepirovirsen, its investigational treatment for chronic hepatitis B. This submission is supported by positive Phase III clinical trial results showing statistically significant functional cure rates. The drug aims to address the significant health burden of chronic hepatitis B, which affects millions in China and worldwide.
Wealth Enhancement Advisory Services LLC Purchases 9,480 Shares of IQVIA Holdings Inc. $IQV
Wealth Enhancement Advisory Services LLC has increased its stake in IQVIA Holdings Inc. by 35.8%, acquiring an additional 9,480 shares and bringing its total holdings to 35,960 shares valued at $8.674 million. IQVIA currently holds a consensus "Buy" rating with a price target of $229.13 and recently surpassed quarterly earnings expectations. The company also issued a positive FY2026 EPS guidance of $12.55–$12.85.
Eagle Rock Investment Company LLC Buys 14,084 Shares of IQVIA Holdings Inc. $IQV
Eagle Rock Investment Company LLC increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 30.4% in the fourth quarter, acquiring an additional 14,084 shares and bringing their total holdings to 60,416 shares valued at $13.62 million. Other institutional investors also adjusted their positions in IQV. Several Wall Street analysts have issued "Buy" or "Overweight" ratings for IQVIA, with an average price target of $229.13.
TD Cowen upgrades IQVIA (IQV) to buy and raises price target to $213
TD Cowen has upgraded IQVIA (IQV) to a "buy" rating and increased its price target to $213. This upgrade reflects a positive outlook on the company's financial prospects and market position. The revised price target suggests a significant upside potential for IQVIA's stock.
IQVIA Holdings Inc. stock underperforms Friday when compared to competitors
IQVIA Holdings Inc. (IQV) stock fell 3.28% on Friday, closing at $163.85, a day when the broader market also experienced declines with the S&P 500 down 1.67% and the Dow Jones Industrial Average down 1.73%. This performance places IQVIA Holdings Inc. 33.68% below its 52-week high of $247.05, reached on January 9th. The article highlights the stock's underperformance relative to major indices.
A Look At IQVIA Holdings (IQV) Valuation After The IQVIA.ai Launch With NVIDIA And Analyst Upgrades
IQVIA Holdings (IQV) recently launched IQVIA.ai in collaboration with NVIDIA, aiming to integrate AI into life sciences workflows. Despite this launch and analyst upgrades, the stock has seen declines over 1 day, 90 days, and 1 year, trading at $163.85. Simply Wall St's "Most Popular Narrative" suggests the stock is 34.5% undervalued with a fair value of $250 per share, attributing this to future earnings power and AI-driven efficiency, though it acknowledges potential challenges from pricing pressure and high leverage.
Vanguard (IQV) Amendment 13G/A: reports 0 shares after realignment
The Vanguard Group filed an Amendment No. 11 to a Schedule 13G/A for IQVIA Holdings Inc., reporting beneficial ownership of 0 shares of Common Stock, representing 0% of the class. This change is due to an internal realignment completed on January 12, 2026, where certain subsidiaries will now report beneficial ownership separately. The filing confirms Vanguard no longer holds, or is deemed to hold, beneficial ownership over these securities.
Invera Wealth Advisors, LLC's IQVIA Holdings Inc(IQV) Holding History
This article details Invera Wealth Advisors, LLC's historical holdings in IQVIA Holdings Inc (IQV) as of December 31, 2025. It shows that Invera Wealth Advisors holds 10,537 shares valued at $2.38 million, representing 1.5% of their portfolio. The firm has made 3 purchases and 5 sales of IQV shares since Q4 2023, resulting in an estimated loss of -15.07% on their current holdings.
IQVIA Holdings Inc Stock: Business Model Strength and Analyst Upgrades Signal Investor Opportunities
IQVIA Holdings Inc (IQV) is highlighted as a global leader in healthcare intelligence, benefiting from a recent Barclays upgrade to overweight with a $210 target price. The company's strong business model leverages vast datasets and AI-driven insights in clinical research and R&D solutions, positioning it well amid rising demand for real-world evidence and personalized medicine. North American investors are encouraged to consider IQV for its resilient healthcare exposure and predictable cash flows, despite risks related to data privacy and client concentration.
IQVIA Holdings Inc. (NYSE:IQV) Given Average Rating of "Buy" by Brokerages
IQVIA Holdings Inc. (NYSE:IQV) has received an average "Buy" rating from seventeen brokerages, with an average 12-month price target of $229.13. The medical research company recently exceeded quarterly earnings and revenue estimates and set a positive FY 2026 EPS guidance. Institutional investors hold a significant stake in IQVIA, with shares currently trading at $169.05, representing a market capitalization of approximately $28.7 billion.
IQV SEC Filings - Iqvia Hldgs Inc 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to IQVIA Holdings Inc. (IQV) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights recent insider transactions where executives received performance-based shares and disposed of others, often to cover tax obligations. The platform also offers AI-powered summaries of these filings to help investors understand key corporate developments and financial information.
Earnings call transcript: OptimizeRx Q4 2025 earnings beat forecasts, stock dips
OptimizeRx (OPRX) reported strong financial results for Q4 2025, with EPS of $0.51 and revenue of $32.2 million, both exceeding forecasts. Despite the earnings beat and a record gross margin of 74.8%, the stock declined 14.36% in after-hours trading, potentially due to broader market conditions or investor concerns about future normalized margins. The company provided 2026 guidance with revenue between $109 million-$114 million and adjusted EBITDA between $21 million-$25 million, reflecting a more conservative view on revenue due to market shifts and client spending adjustments.
IQV SEC Filings - Iqvia Hldgs Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for IQVIA Holdings Inc. (IQV) SEC filings, including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms. It highlights recent filings from October and November 2025, detailing director share acquisitions, executive stock appreciation rights exercises and sales, board appointments, and the company's Q3 2025 financial results. The platform, Stock Titan, offers AI-powered summaries and sentiment analysis for these regulatory documents.
Is IQVIA.ai’s NVIDIA‑Powered Platform Altering The Investment Case For IQVIA Holdings (IQV)?
IQVIA Holdings recently launched IQVIA.ai, an NVIDIA-powered AI platform designed to embed healthcare-grade AI into life sciences workflows. This platform, along with an expanded partnership with Salesforce, aims to strengthen IQVIA's data and AI integration within pharmaceutical processes and reinforce switching costs. While the new platform offers AI-enabled differentiation, analysts note that intense CRO competition and pricing pressures remain significant risks to IQVIA's investment narrative.
IQVIA Holdings Forms Death Cross, Signaling Potential Bearish Trend Ahead
IQVIA Holdings, Inc. has experienced a "Death Cross" technical event, where its short-term moving average fell below its long-term moving average, signaling potential bearish momentum. The stock has significantly underperformed the S&P 500 over the past year and year-to-date, indicating a challenging market position and potential for further declines.
IQVIA Holdings Inc. $IQV Stock Position Decreased by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 8.7% during the fourth quarter, selling 21,374 shares. Despite this, other institutional investors increased their positions in IQVIA. The medical research company has an average "Buy" rating from analysts with an average price target of $229.13, and recently beat earnings estimates for the latest quarter.
ICON, Advarra Partner on Connected Site Network Model
ICON plc and Advarra have formed a strategic partnership to develop a "research-ready" connected site network model for clinical trials. This collaboration aims to integrate ICON’s global clinical trial services with Advarra’s site systems, including CTMSs, eISF, and eSource, to streamline operations. The goal is to reduce administrative burdens, accelerate study startup, and improve overall clinical trial participation and efficiency by leveraging Advarra's operational intelligence platform.
TD Cowen upgrades IQVIA (IQV) to buy and raises price target to $213
TD Cowen has upgraded its rating for IQVIA (IQV) from market perform to buy. The firm also increased its price target for IQV shares to $213. This indicates a positive outlook on the company's future performance by TD Cowen.
TD Cowen Upgrades IQVIA (IQV) to Buy and Raises Price Target to $213
TD Cowen has upgraded IQVIA Holdings Inc. (IQV) to Buy from Hold and increased its price target to $213, citing an attractive risk-reward opportunity after a 24% share price decline. Analysts believe IQVIA will remain resilient against AI-driven revenue headwinds, expecting savings from AI to be reinvested into research. This upgrade follows a similar move by Barclays, which also upgraded IQV to Overweight with a $210 price target.
Community Trust & Investment Co. Reduces Stock Holdings in IQVIA Holdings Inc. $IQV
Community Trust & Investment Co. significantly reduced its stake in IQVIA Holdings Inc. by 7.9% in the fourth quarter, now owning 100,312 shares valued at $22.611 million. Despite this reduction, IQVIA demonstrated strong financial performance, exceeding Q4 earnings and revenue expectations and receiving broad analyst support with a "Buy" rating and an average target price of $229.13. Several other hedge funds, however, increased their positions in the medical research company during the same period.
IQVIA Holdings Inc. $IQV Shares Acquired by Diversified Trust Co.
Diversified Trust Co. has increased its stake in IQVIA Holdings Inc. by 14.8% to 48,876 shares, now valued at $11.017 million. Institutional investors collectively own about 89.62% of the company's stock. Analysts currently hold a "Buy" rating for IQVIA, with an average price target of $229.13, following the company's recent strong Q4 earnings report where it surpassed revenue and EPS estimates.
IQVIA Holdings, Inc. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators
IQVIA Holdings, Inc. has seen a revision in its stock evaluation, with its current price at $166.07 after experiencing significant volatility over the past year. Technical indicators like MACD, RSI, and Bollinger Bands present a mixed outlook, with some indicating bearish trends while others are mildly bullish. The company's stock performance has consistently underperformed the S&P 500, highlighting challenges in a competitive market.
Nordea Investment Management AB Sells 1,600,906 Shares of IQVIA Holdings Inc. $IQV
Nordea Investment Management AB significantly reduced its stake in IQVIA Holdings Inc. by selling 1,600,906 shares in the fourth quarter, retaining 713,313 shares valued at $161.5 million. Despite this, Wall Street analysts maintain a positive outlook with a consensus "Buy" rating and an average price target of $229.13. IQVIA recently surpassed quarterly revenue and EPS estimates, showing 10.3% year-over-year revenue growth and providing strong FY2026 EPS guidance.
TD Cowen Maintains IQVIA Holdings(IQV.US) With Buy Rating, Raises Target Price to $213
TD Cowen has reiterated its Buy rating on IQVIA Holdings (IQV.US) and increased its price target to $213. This indicates continued confidence in the company's performance and future growth prospects from the analyst firm.
IQV SEC Filings - Iqvia Hldgs Inc 10-K, 10-Q, 8-K Forms
This article provides access to IQVIA Holdings Inc. (IQV) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. It highlights how these documents offer insights into the company's financial health, governance, and operations. The platform also utilizes AI-powered summaries to interpret lengthy filings for investors.
